Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PLM-102 |
| Synonyms | |
| Therapy Description |
PLM-102 inhibits FLT3 and RET, decreasing downstream signaling and potentially inducing apoptosis and inhibiting tumor growth (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) e15103). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PLM-102 | PLM102|PLM 102 | FLT3 Inhibitor 69 RET Inhibitor 53 | PLM-102 inhibits FLT3 and RET, decreasing downstream signaling and potentially inducing apoptosis and inhibiting tumor growth (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) e15103). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07549464 | Phase I | PLM-102 | Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |